Provided by Tiger Fintech (Singapore) Pte. Ltd.

TG Therapeutics

43.44
-1.9300-4.25%
Post-market: 43.600.1625+0.37%19:56 EDT
Volume:4.17M
Turnover:184.69M
Market Cap:6.90B
PE:289.60
High:45.97
Open:45.37
Low:42.96
Close:45.37
Loading ...

TG Therapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
03 Mar

TG Therapeutics Swings to Q4 Net Income, Revenue Rises; 2025 Revenue Guidance Set

MT Newswires Live
·
03 Mar

TG Therapeutics Expects Full Year 2025 Revenue Of Approximately $540M Versus Consensus Of $548.20M, Including Briumvi U.S. Net Product Revenue Of Approximately $525M

Benzinga
·
03 Mar

GUIDANCE: (TGTX) TG Therapeutics Expects Full Year 2025 Global Revenue About $540M, vs. FactSet Est of $534.4M

MT Newswires Live
·
03 Mar

Earnings Flash (TGTX) TG Therapeutics Posts Q4 EPS $0.15, vs. FactSet Est of $0.16

MT Newswires Live
·
03 Mar

TG Therapeutics Q4 2024 GAAP EPS $0.15, Inline, Sales $108.19M Beat $99.95M Estimate

Benzinga
·
03 Mar

TG Therapeutics Q4 Operating Income USD 29.949 Million

THOMSON REUTERS
·
03 Mar

TG Therapeutics Inc - Target Guidance of $540 Million in Total Global Revenue for 2025

THOMSON REUTERS
·
03 Mar

Risks To Shareholder Returns Are Elevated At These Prices For TG Therapeutics, Inc. (NASDAQ:TGTX)

Simply Wall St.
·
02 Mar

TG Therapeutics Inc expected to post earnings of 8 cents a share - Earnings Preview

Reuters
·
28 Feb

TG Therapeutics Announces Presentation of Data for Briumvi® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

THOMSON REUTERS
·
27 Feb

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

GlobeNewswire
·
27 Feb

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update

GlobeNewswire
·
26 Feb

Institutional investors in TG Therapeutics, Inc. (NASDAQ:TGTX) see US$243m decrease in market cap last week, although long-term gains have benefitted them.

Simply Wall St.
·
25 Feb

BRIEF-TG Therapeutics Announces Schedule Of Data Presentations For Briumvi® (Ublituximab) In Multiple Sclerosis At The Americas Committee For Treatment And Research In Multiple Sclerosis Annual Forum

Reuters
·
18 Feb

TG Therapeutics Announces Schedule of Data Presentations for Briumvi® (Ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

THOMSON REUTERS
·
18 Feb

How Small, But 'Mighty' TG Therapeutics Scored A 470% Gain Over 13 Months

Blockhead
·
12 Feb

MaxCyte enters strategic platform license with TG Therapeutics

TIPRANKS
·
12 Feb

MaxCyte Licenses Cell-Engineering Technology to TG Therapeutics

MT Newswires Live
·
12 Feb

Bank of America Securities Sticks to Its Sell Rating for TG Therapeutics (TGTX)

TIPRANKS
·
11 Feb